Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology
Source: SeekingAlpha
2025-05-02 12:28:11 ET
More on Fulgent Genetics
- Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript
- Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
- Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript
- Fulgent Genetics rises on earnings, revenue beat
- Fulgent Genetics beats top-line and bottom-line estimates; reaffirms FY25 outlook
Read the full article on Seeking Alpha
For further details see:
Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology
Fulgent Genetics Inc.
NASDAQ: FLGT
FLGT Trading
3.59% G/L:
$14.855 Last:
371,380 Volume:
$14.66 Open:
FLGT Latest News
February 12, 2026 07:30:00 am
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
FLGT Stock Data
$726,441,212
20,677,299
5.21%
56
N/A
Medical Diagnostics & Screening
Healthcare
US
El Monte
